Excess Deaths Upon Cessation of Xanthine Oxidase Inhibitor Treatment-Data From the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial: Comment on the Article by Choi et al
- PMID: 31022328
- DOI: 10.1002/art.40914
Excess Deaths Upon Cessation of Xanthine Oxidase Inhibitor Treatment-Data From the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial: Comment on the Article by Choi et al
Comment on
-
New Perspectives in Rheumatology: Implications of the Cardiovascular Safety of Febuxostat and Allopurinol in Patients With Gout and Cardiovascular Morbidities Trial and the Associated Food and Drug Administration Public Safety Alert.Arthritis Rheumatol. 2018 Nov;70(11):1702-1709. doi: 10.1002/art.40583. Arthritis Rheumatol. 2018. PMID: 29869840 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
